Arix Bioscience Plc Clinical progress from Autolus
September 18 2017 - 2:20AM
RNS Non-Regulatory
TIDMARIX
Arix Bioscience Plc
18 September 2017
Arix Bioscience plc notes positive clinical study announcements
from Autolus Limited
LONDON, 18 September 2017: Arix Bioscience plc (LSE: ARIX)
("Arix Bioscience"), a global healthcare and life science company
supporting medical innovation, is pleased to note two positive
press releases today by Autolus Limited ("Autolus"), an Arix
Bioscience Group Business, announcing clinical progress across its
portfolio.
The first release today from Autolus announced the completion of
the first-dose cohort of its Phase I/II study of AUTO2, its novel,
dual-targeted Chimeric Antigen Receptor (CAR) in patients with
relapsed/refractory melanoma.
Autolus' AUTO2 is a CAR-T cell therapy that targets both B-cell
maturation antigen (BCMA) and transmembrane activator and calcium
modulator and cyclophilin ligand interactor (TACI). AUTO2
re-programmes the patient's own T cells to minimize the risk of
cancer cells escaping treatment. AUTO2 is the first example of
Autolus' approach to unlocking the curative potential of CAR-T cell
therapies.
The second release today from Autolus announced initiation of
both the AMELIA and ALEXANDER Phase I/II studies for AUTO3, its
novel, dual-targeting, AUTO3 CAR T cell therapy, for paediatric
Acute Lymphocytic Leukaemia (ALL) and adult Diffuse Large B-Cell
Lymphoma (DLBCL).
Autolus' AUTO3 seeks to overcome two limitations of current
therapies by introducing dual targeting CARs and addressing
checkpoint mediated inhibition.
Joe Anderson, Chief Executive Officer of Arix Bioscience,
commented: "Cell therapy has the potential to advance cancer
treatment substantially and the announcements today from Autolus
are an important step in this campaign. CAR-T is a proven, new
approach to cancer treatment and Autolus has the science and the
team to substantially advance this field, with a differentiated
technology. We are privileged to work with the company and our
co-investors to help advance these goals."
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052
Matthew Cole, Communications Director
+44 (0) 20 7290 1065
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in London and
with an office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange.
For further information, please visit www.arixbioscience.com
About Autolus Limited
Autolus is a clinical-stage, biopharmaceutical company, focused
on the development and commercialisation of engineered T-cell
immunotherapy products to combat cancer. Utilising its advanced
cell programming and manufacturing technologies, Autolus has a
pipeline of products in development for the treatment of both
haematological malignancies and solid tumours. For further
information please visit the Company's website at:
www.autolus.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFNXFFKXEAF
(END) Dow Jones Newswires
September 18, 2017 02:20 ET (06:20 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024